New drug combo aims to outsmart resistant leukemia
NCT ID NCT06399640
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether combining two oral drugs, eltanexor and venetoclax, is safe and effective for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study will enroll 60 adults and look for the best dose and any signs of remission. Both drugs work by blocking proteins that help cancer cells survive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eltanexor and venetoclax
What this could lead to
If this works, it could offer a new treatment option for people with blood cancers that have stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so it is primarily testing safety and dosing. It may not lead to a proven treatment, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baptist Health Care Corporation
RECRUITINGMemphis, Tennessee, 38138, United States
Contact Email: •••••@•••••
-
Vanderbilt University/Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••